WORDSWORTH-20131028124045...FDA has clearly argued against unique INNS for biosimilars when it...
23
Transcript of WORDSWORTH-20131028124045...FDA has clearly argued against unique INNS for biosimilars when it...
![Page 1: WORDSWORTH-20131028124045...FDA has clearly argued against unique INNS for biosimilars when it stated: "INNs should not be used to imply pharmacologic interchangeability of products](https://reader034.fdocuments.in/reader034/viewer/2022050115/5f4c3692cda8651071774f97/html5/thumbnails/1.jpg)
![Page 2: WORDSWORTH-20131028124045...FDA has clearly argued against unique INNS for biosimilars when it stated: "INNs should not be used to imply pharmacologic interchangeability of products](https://reader034.fdocuments.in/reader034/viewer/2022050115/5f4c3692cda8651071774f97/html5/thumbnails/2.jpg)
![Page 3: WORDSWORTH-20131028124045...FDA has clearly argued against unique INNS for biosimilars when it stated: "INNs should not be used to imply pharmacologic interchangeability of products](https://reader034.fdocuments.in/reader034/viewer/2022050115/5f4c3692cda8651071774f97/html5/thumbnails/3.jpg)
![Page 4: WORDSWORTH-20131028124045...FDA has clearly argued against unique INNS for biosimilars when it stated: "INNs should not be used to imply pharmacologic interchangeability of products](https://reader034.fdocuments.in/reader034/viewer/2022050115/5f4c3692cda8651071774f97/html5/thumbnails/4.jpg)
![Page 5: WORDSWORTH-20131028124045...FDA has clearly argued against unique INNS for biosimilars when it stated: "INNs should not be used to imply pharmacologic interchangeability of products](https://reader034.fdocuments.in/reader034/viewer/2022050115/5f4c3692cda8651071774f97/html5/thumbnails/5.jpg)
![Page 6: WORDSWORTH-20131028124045...FDA has clearly argued against unique INNS for biosimilars when it stated: "INNs should not be used to imply pharmacologic interchangeability of products](https://reader034.fdocuments.in/reader034/viewer/2022050115/5f4c3692cda8651071774f97/html5/thumbnails/6.jpg)
![Page 7: WORDSWORTH-20131028124045...FDA has clearly argued against unique INNS for biosimilars when it stated: "INNs should not be used to imply pharmacologic interchangeability of products](https://reader034.fdocuments.in/reader034/viewer/2022050115/5f4c3692cda8651071774f97/html5/thumbnails/7.jpg)
![Page 8: WORDSWORTH-20131028124045...FDA has clearly argued against unique INNS for biosimilars when it stated: "INNs should not be used to imply pharmacologic interchangeability of products](https://reader034.fdocuments.in/reader034/viewer/2022050115/5f4c3692cda8651071774f97/html5/thumbnails/8.jpg)
![Page 9: WORDSWORTH-20131028124045...FDA has clearly argued against unique INNS for biosimilars when it stated: "INNs should not be used to imply pharmacologic interchangeability of products](https://reader034.fdocuments.in/reader034/viewer/2022050115/5f4c3692cda8651071774f97/html5/thumbnails/9.jpg)
![Page 10: WORDSWORTH-20131028124045...FDA has clearly argued against unique INNS for biosimilars when it stated: "INNs should not be used to imply pharmacologic interchangeability of products](https://reader034.fdocuments.in/reader034/viewer/2022050115/5f4c3692cda8651071774f97/html5/thumbnails/10.jpg)
![Page 11: WORDSWORTH-20131028124045...FDA has clearly argued against unique INNS for biosimilars when it stated: "INNs should not be used to imply pharmacologic interchangeability of products](https://reader034.fdocuments.in/reader034/viewer/2022050115/5f4c3692cda8651071774f97/html5/thumbnails/11.jpg)
![Page 12: WORDSWORTH-20131028124045...FDA has clearly argued against unique INNS for biosimilars when it stated: "INNs should not be used to imply pharmacologic interchangeability of products](https://reader034.fdocuments.in/reader034/viewer/2022050115/5f4c3692cda8651071774f97/html5/thumbnails/12.jpg)
![Page 13: WORDSWORTH-20131028124045...FDA has clearly argued against unique INNS for biosimilars when it stated: "INNs should not be used to imply pharmacologic interchangeability of products](https://reader034.fdocuments.in/reader034/viewer/2022050115/5f4c3692cda8651071774f97/html5/thumbnails/13.jpg)
![Page 14: WORDSWORTH-20131028124045...FDA has clearly argued against unique INNS for biosimilars when it stated: "INNs should not be used to imply pharmacologic interchangeability of products](https://reader034.fdocuments.in/reader034/viewer/2022050115/5f4c3692cda8651071774f97/html5/thumbnails/14.jpg)
![Page 15: WORDSWORTH-20131028124045...FDA has clearly argued against unique INNS for biosimilars when it stated: "INNs should not be used to imply pharmacologic interchangeability of products](https://reader034.fdocuments.in/reader034/viewer/2022050115/5f4c3692cda8651071774f97/html5/thumbnails/15.jpg)
![Page 16: WORDSWORTH-20131028124045...FDA has clearly argued against unique INNS for biosimilars when it stated: "INNs should not be used to imply pharmacologic interchangeability of products](https://reader034.fdocuments.in/reader034/viewer/2022050115/5f4c3692cda8651071774f97/html5/thumbnails/16.jpg)
![Page 17: WORDSWORTH-20131028124045...FDA has clearly argued against unique INNS for biosimilars when it stated: "INNs should not be used to imply pharmacologic interchangeability of products](https://reader034.fdocuments.in/reader034/viewer/2022050115/5f4c3692cda8651071774f97/html5/thumbnails/17.jpg)
![Page 18: WORDSWORTH-20131028124045...FDA has clearly argued against unique INNS for biosimilars when it stated: "INNs should not be used to imply pharmacologic interchangeability of products](https://reader034.fdocuments.in/reader034/viewer/2022050115/5f4c3692cda8651071774f97/html5/thumbnails/18.jpg)
![Page 19: WORDSWORTH-20131028124045...FDA has clearly argued against unique INNS for biosimilars when it stated: "INNs should not be used to imply pharmacologic interchangeability of products](https://reader034.fdocuments.in/reader034/viewer/2022050115/5f4c3692cda8651071774f97/html5/thumbnails/19.jpg)
![Page 20: WORDSWORTH-20131028124045...FDA has clearly argued against unique INNS for biosimilars when it stated: "INNs should not be used to imply pharmacologic interchangeability of products](https://reader034.fdocuments.in/reader034/viewer/2022050115/5f4c3692cda8651071774f97/html5/thumbnails/20.jpg)
![Page 21: WORDSWORTH-20131028124045...FDA has clearly argued against unique INNS for biosimilars when it stated: "INNs should not be used to imply pharmacologic interchangeability of products](https://reader034.fdocuments.in/reader034/viewer/2022050115/5f4c3692cda8651071774f97/html5/thumbnails/21.jpg)
![Page 22: WORDSWORTH-20131028124045...FDA has clearly argued against unique INNS for biosimilars when it stated: "INNs should not be used to imply pharmacologic interchangeability of products](https://reader034.fdocuments.in/reader034/viewer/2022050115/5f4c3692cda8651071774f97/html5/thumbnails/22.jpg)
![Page 23: WORDSWORTH-20131028124045...FDA has clearly argued against unique INNS for biosimilars when it stated: "INNs should not be used to imply pharmacologic interchangeability of products](https://reader034.fdocuments.in/reader034/viewer/2022050115/5f4c3692cda8651071774f97/html5/thumbnails/23.jpg)